All News
ATOM study, Abs 1314, greater proportion of men with OP on abaloparatide vs placebo met the definition of a >3% responder at the LS, TH, and FN. #ACR22 @RheumNow https://t.co/q6gcX5Azts https://t.co/WEjqbl14ZN
Dr. Rachel Tate uptoTate ( View Tweet)
Benefits with receiving anabolic agents upfront before antiresoprtives (as opposed to other way around). Shame about lack of access to this sequence currently
@RheumNow #ACR22 #osteoporosis https://t.co/S2ttbrVaab
Julian Segan JulianSegan ( View Tweet)
Romo works even better in higher risk patients. More ammunition to use up-front. Availability is a limiting factor though.
@RheumNow #ACR22 #osteoporosis https://t.co/90X97jVJcP
Julian Segan JulianSegan ( View Tweet)
Emphasis that drug holiday is NOT drug retirement in osteoporosis. Ideal time to re-initiate is quite uncertain however. Continue to monitor DEXA and fracture risk factors.
@RheumNow #ACR22 #osteoporosis https://t.co/iLKrxdzpAR
Julian Segan JulianSegan ( View Tweet)
Atypical femoral fracture risk increases over time. Risk decreases slowly as well with time off treatment. Absolute risk remains relatively low however.
@RheumNow #ACR22 #osteoporosis https://t.co/pcIfhRW4WJ
Julian Segan JulianSegan ( View Tweet)
Good BMD gains in switching BP->denosumab, especially in first few years. #sequentialtherapy
@RheumNow #ACR22 #osteoporosis https://t.co/t1hItKn8sB
Julian Segan JulianSegan ( View Tweet)
Osteoporotic fx in AS
Abstract #0388 #ACR22 @RheumNow
🦴2k adults in RISE, mean age 68y, 44% female, 76% white
🦴Higher risk with: older age, increased comorbidity index, OP history, chronic use of opioids, low BMI
🦴Men and women were equally likely to fracture
Catherine Sims, MD DrCassySims ( View Tweet)
Limited utility for using bone turnover markers in osteoporosis. Perhaps useful to assess adherence to oral therapy.
@RheumNow #ACR22 #osteoporosis https://t.co/g6f7SnOzNR
Julian Segan JulianSegan ( View Tweet)
Ab0575 #ACR22 MI/CVA in Osteoporosis Pts on DEN/ ZOL, L Spangler
DEN pts more likely CKD, adjusted analysis
At 36 mos, risk for Den vs Zol in 2 database claims:
- MI: 0.97, 1.22 (0.8-1.7)
- CVA: 0.9 (0.6-1.2), 1.0
No incr. risk identified with Den vs Zol in MI or CVA
@RheumNow https://t.co/hgyG1ZmFLT
Eric Dein ericdeinmd ( View Tweet)
Ab0574 #ACR22: Osteoporosis in Men - Under-recognized? Under-Screened? Under-Diagnosed!
@AMollaeianMD: Retrosp study >65 yo
<1% M have DEXA compared to 7-10% in F in 2010, 2018, and 2021
Hip fx 4.1% F, 3% M
DEXA declined in M between 2010-2018, no change in 2021
🦴🦴🩻
@RheumNow https://t.co/LbmxLnIX1Q
Eric Dein ericdeinmd ( View Tweet)
Which one to use for prevention and which for treatment? Drugs covered by #Medicare based on indication #osteoporosis #acr22 #acrreview @RheumNow https://t.co/KE5F6Sn3wg
TheDaoIndex KDAO2011 ( View Tweet)
#osteoporosis baseline lab work should be completed to assess for secondary causes. DEXA is underutilized in men and should be considered especially in men with inflammatory disease
Baseline labs: CBC, BMP, PTH, vit D, TSH, urine ca, testosterone #ACR22 @RheumNow https://t.co/byXLQFpe3n
Catherine Sims, MD DrCassySims ( View Tweet)
Medicare will cover #DXA testing for these diagnoses @RheumNow #acr22 #acrreview https://t.co/keZg0fxyz9
TheDaoIndex KDAO2011 ( View Tweet)
Did You Know? FDA relaxed warnings on #sarcoma with #Forteo- can use more than 2 years @RheumNow #acr22 #acrreview #osteoporosis https://t.co/Xzr6TZIlWN
TheDaoIndex KDAO2011 ( View Tweet)
Drug holidays for #osteoporosis RX but be note fracture risk may increase with these holidays- consider an anabolic agent during these times - Dr Tanner #acr22 @RheumNow #acrreview https://t.co/6XbpYD5D1X
TheDaoIndex KDAO2011 ( View Tweet)
Dr Tanner presents the features of AFF👇
It is rare, subtrochanteric in location and often appears w/n 5-10 yrs of BP use.
#ACR22 @RheumNow #acrreview #osteoporosis https://t.co/KbMJ4dXfpj
sheila RHEUMarampa ( View Tweet)
P1NP is a useful bone turnover marker that Dr. Tanner checks to monitor #osteoporosis therapy (if insurance covers it) - it is not affected by diurnal variation, food, renal function. #ACR22 @rheumnow #ACRReview
TheDaoIndex KDAO2011 ( View Tweet)
Full read review of advances in bone biology leading to drug development (denosumab, romosuzumab, Burosumab), advances in Pagets and rickets and key regulatory molecules for bone remodeling, RANK, RANKL, OPG, & sclerostin https://t.co/CMMzIrZRUa https://t.co/ABhaHxP8y2
Links:
Dr. John Cush RheumNow ( View Tweet)
Popular Post: 2022 New ACR Guidance on Glucocorticoid-Induced Osteoporosis (GIOP)
The ACR has updated this guideline and includes recommendations on abaloparatide (PTHrP) and romosozumab, which are newly available since the ACR’s 2017 GIOP guideline.
https://t.co/1LEtUvjNUG https://t.co/IYaJzZmg39
Links:
Dr. John Cush RheumNow ( View Tweet)
Review of risk factors for osteoporosis and fractures in #RA. OP Risk factors same as gen population (but more prevalent in RA) - smoking, calcium intake, vit D deficiency, hypogonadism and chronic exposure to glucocorticoids https://t.co/KsE5ag29ZN https://t.co/OQtfoKcIX2
Links:
Dr. John Cush RheumNow ( View Tweet)
